Royalty Pharma stock
Price history
+75.77% over the period1 year: from $39.16 (November 17, 2025) to $68.83 (November 16, 2026), +75.77%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | $68.83 |
| October 30, 2026 | $67.18 |
| September 30, 2026 | $58.36 |
| August 31, 2026 | $61.41 |
| July 31, 2026 | $58.43 |
| June 30, 2026 | $56.07 |
| May 29, 2026 | $55.76 |
| April 30, 2026 | $50.09 |
| March 31, 2026 | $47.97 |
| February 27, 2026 | $46.21 |
| January 30, 2026 | $41.68 |
| December 31, 2025 | $38.64 |
| November 28, 2025 | $40.02 |
| November 17, 2025 | $39.16 |
At a glance
The company
Buyer of biopharmaceutical royalties and funder of innovation in the biopharmaceutical industry
Latest results
Quarter to September 30, 2026 · EPS $1.21 (estimate $1.18)
TickerLandia's take on Royalty Pharma
- Pricier than usual relative to earnings: P/E on the latest fiscal year 39 vs a median of 22 over its last 5 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 45 vs 39 (+15%) in a group of 6.
- Strong point: Market momentum (92/100 in its group). Weak point: Financial strength (15/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−2.19% from the 52-week high
Analysts · 9 analysts
Average target$72.00+4.61% vs. price
Buy 7 · Hold 2 · Sell 0 · Buy
TickerLandia Fingerprint: Royalty Pharma
Compared with similar companies: very strong momentum, very low financial strength, and very low risk.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.
Priceaverage44
How much it costs relative to what it produces.
Metric Value Position in group Forward P/E 11.7 10 EV/EBITDA 24.8 51 Price/book 4.52 34 Price/sales 15.2 64 P/E (trailing 12 months) 45.3 60 Profitabilityhigh73
How much it earns on revenue and capital.
Metric Value Position in group Gross margin 99.8% 94 Operating margin 64.4% 98 ROA 5.4% 51 Net margin 25.7% 68 ROE 12.1% 55 Earnings stabilityhigh79
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 9.8% 75 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 84 Growthlow24
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) +2.06% 10 Revenue growth (year over year) +13.30% 34 Earnings growth (year over year) −50.80% 28 Financial strengthvery low15
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 5.34 4 Debt/equitycounts in reverse: lower means more financial strength 0.88 9 Current ratio 1.29 7 Interest coverage 5.07 40 Dividendhigh68
How much it returns to shareholders, and for how long.
Metric Value Position in group Consecutive dividend years at least 7 years 65 Dividend yield 1.4% 64 Payout ratio 61.4% 75 Market momentumvery strong92
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +22.07% 93 Relative strength (6 months) +28.14% 84 Distance from 200-day average +26.88% 94 1-year return +74.45% 95 Riskvery low18
How much the price swings.
Metric Value Position in group Volatility (60 days) 23.7% 21 Beta (1 year) 0.24 28 Maximum drawdown (12 months) 12.1% 3
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Royalty Pharma is pricier than in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Royalty Pharma's P/E today is 38.6, above the median of its last 5 fiscal years (21.7; between 11.1 and 37.9 from 2020 to 2025). Royalty Pharma's P/E (trailing 12 months): 45.3, +15% against the median of a group of 6 similar companies (39.3).
Compared with 6 similar companies
| Metric | Royalty Pharma | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 45.3 | Middle | |
| Forward P/E | 11.7 | Low | |
| Operating margin | 64.4% | High | |
| ROE | 12.1% | Middle | |
| Debt/equity | 0.88 | High |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Royalty Pharma. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
$674.14M
Latest quarter · Q2 2026
Net income
$17.88M
Latest quarter · Q2 2026
Quarterly net margin
2.7%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $39.85B
- P/E
- 45.3
- EPS
- $1.53
- Volume
- 2.95M
- Daily trading
- €204.78M
- Dividend yield
- 1.37%
- Last ex-dividend on November 13, 2026
How Royalty Pharma is changing
All resultsRevenue grew 2.3% a year on average over the last 5 years
Operating margin rose from 41.3% to 65.6%
Shares outstanding up 50.3% in 5 years
Returns
Royalty Pharma returns with dividends
$1,000 invested in Royalty Pharma 5 years ago, on November 16, 2021, would be worth $1,848 today with dividends reinvested: +84.79% in total, +13.07% per year. On price alone it would be $1,639 (+63.92%).
| Period | Royalty Pharma | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | +12.91% | −3.12% | $1,129 |
| 6 months | +30.24% | +2.07% | $1,302 |
| Year to date | +78.13% | +10.46% | $1,781 |
| 1 year | +78.78% | +13.33% | $1,788 |
| 3 years | +178.80% | +67.73% | $2,788 |
| 5 years | +84.79% | +60.86% | $1,848 |
Over the last 6 months it has done better than 66% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
Royalty Pharma: technical analysis
Royalty Pharma is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 1.7% below its all-time closing high ($70.01, November 11, 2026).
- Trend
- Upward
- RSI (14 sessions)
- 69
- Between 30 and 70
- vs 200-session average
- +25.69%
Support and resistance
Price areas where Royalty Pharma has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price$68.83
- Support$56.31−18.19%3 touches, last on August 4, 2026
- Support$55.04−20.03%2 touches, last on October 8, 2026
- Support$49.09−28.69%2 touches, last on May 4, 2026
Volatility and risk
Over the last year it has moved little with the S&P 500.
- Beta (1 year) vs S&P 500
- 0.24
- Volatility (60 sessions, annualised)
- 23.7%
- Largest fall in the last year
- −12.12%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Royalty Pharma: seasonality
Average monthly price change over 7 years
Over the last 7 years, the strongest month for Royalty Pharma has been November: +4.45% on average, positive in 5 years out of 6. The weakest has been September: −3.88% on average, positive in 1 years out of 7.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +4.37% | +0.73% | 4 of 6 |
| February | +2.15% | +2.79% | 3 of 6 |
| March | −1.69% | −0.33% | 3 of 6 |
| April | +1.46% | +2.65% | 4 of 6 |
| May | −1.43% | −2.21% | 2 of 6 |
| June | +0.76% | +1.36% | 4 of 6 |
| July | +0.08% | +2.14% | 5 of 7 |
| August | −0.80% | −2.23% | 3 of 7 |
| September | −3.88% | −3.90% | 1 of 7 |
| October | +2.56% | +5.33% | 4 of 7 |
| November | +4.45% | +2.32% | 5 of 6 |
| December | +0.60% | −1.62% | 3 of 6 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Royalty Pharma and its competitors
Royalty Pharma plc is known by its royalty portfolio on medicines, which covers about 35 marketed therapies and around 20 development-stage product candidates. The company buys biopharmaceutical royalties and funds innovation in the biopharmaceutical industry, with a portfolio spanning rare disease, oncology, neuroscience, infectious disease, hematology and diabetes. It also has a research and development funding collaboration to advance JNJ-4804, an investigational medicine for autoimmune diseases.
- Headquarters
- New York, United States
- Employees
- 100
- Founded
- 1996
- Chief executive
- Pablo Legorreta
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| Royalty PharmaRPRX | $39.85B | 64.4% | 45.3 | +30.24% |
| Revolution MedicinesRVMD | $37.27B | -853.0% | — | +15.07% |
| BeOne MedicinesONC | $47.58B | 17.8% | 53.4 | +41.17% |
| Roivant SciencesROIV | $28.64B | -3,226.3% | — | +33.87% |
| InsmedINSM | $26.58B | -41.7% | — | +13.65% |
| argenxARGX | $60.37B | 31.9% | 33.3 | +20.40% |
Same industry or related industries, similar size. Compare Royalty Pharma with its competitors · Full profile
